Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony (2024) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

<img xmlns="http://www.w3.org/1999/xhtml" src="https://pub.demo35.eprints-hosting.org/349/3.haslightboxThumbnailVersion/305260.pdf" class="document_preview_tile_thumbnail"/> <span xmlns="http://www.w3.org/1999/xhtml" title="305260.pdf">305260.pdf</span>
305260.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB)
Abstract

Aim: The cost–effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed.

Materials and methods: A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost–effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY).

Results: Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses.

Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.

Information
Title Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland
Creators Critchlow, Simone and Bullement, Ash and Crabb, Simon and Jones, Robert and Christoforou, Katerina and Amin, Amerah and Xiao, Ying and Kapetanakis, Venediktos and Benedict, Ágnes and Chang, Jane and Kearney, Mairead and Eccleston, Anthony
Identification Number 10.2217/fon-2023-0372
Date March 2024
Divisions College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Publisher Future Medicine
Additional Information This study was sponsored by Merck (CrossRef Funder ID: 10.13039/100009945) and was previously conducted under an alliance between Merck and Pfizer.
Library
URI https://pub.demo35.eprints-hosting.org/id/eprint/349
Item Type Article
Depositing User Unnamed user with email ejo1f20@soton.ac.uk
SWORD Depositor Users 37347 not found.
Date Deposited 11 Jun 2025 16:37
Revision 17
Last Modified 12 Jun 2025 10:21
View Item